BI 1569912 vs Blixeprodil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
BI 1569912
Developed by Boehringer Ingelheim
NCT06280235 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 243 participants, using the clinical MADRS depression score as its primary endpoint. However, the prespecified primary dose-response analysis was not statistically significant, so the trial provides well-controlled but inconclusive evidence of benefit.
Reported efficacy
Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): 5 mg BI 1569912 -13.6 Units on a scale (95% CI -17.8 to -9.4) | 10 mg BI 1569912 -10.6 Units on a scale (95% CI -14.5 to -6.7) | 20 mg BI 1569912 -10 Units on a scale (95% CI -12.9 to -7.2) vs Placebo-matching BI 1569912 -10.3 Units on a scale (95% CI -13.1 to -7.5) (missed)
Result source: NCT06558344
Blixeprodil
Developed by Gilgamesh Pharma
NCT06309277 · Phase 2 · completed
This two-part, randomized, quadruple-blind, placebo-controlled Phase 2a study gave single and multiple oral doses of GM-1020 (blixeprodil) or placebo to 46 patients with major depressive disorder. The only registered primary outcome is the incidence of treatment-emergent adverse events, which has no formal efficacy test, so there is no met or missed result. Antidepressant response was a preliminary, non-primary aim. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment Emergent Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Incidence of Treatment Emergent Adverse Events (Baseline, Day 29): Primary outcome, incidence of treatment-emergent adverse events to Day 29 (no formal efficacy test): Part A, 23 participants on placebo and 43 on GM-1020 140 mg with at least one TEAE (CT.gov posted results). (not_applicable)
Result source: NCT06309277
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BI 1569912 | Blixeprodil |
|---|---|---|
| MADRS, change (acute) | -12.3 vs -12−0.3 vs placeboNCT0628023510 other results
| -10.5 vs -5.4−5.1 vs placeboNCT063092771 other result
|
| CGI-S, change (acute) | —Not reported | —Not reported |
| MADRS response | 34.8% vs 33.8%+1 vs placeboNCT062802355 other results
| —Not reported |
| MADRS remission | 21.2% vs 19.7%+1.5 vs placeboNCT062802352 other results
| —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
MADRS, change (acute)
- BI 1569912
- -12.3 vs -12−0.3 vs placeboNCT06280235
10 other results
- -10 vs -10.3 NCT06558344
- -19.9 vs -19.3 NCT04937829
- -11.9 vs -12 NCT06280235
- -10.6 vs -10.3 NCT06558344
- -16.8 vs -19.3 NCT04937829
- -7.8 vs -12 NCT06280235
- -13.6 vs -10.3 NCT06558344
- -5.7 vs -6.4 NCT06280235
- -5.9 vs -6.4 NCT06280235
- -5.2 vs -6.4 NCT06280235
- Blixeprodil
- -10.5 vs -5.4−5.1 vs placeboNCT06309277
1 other result
- -12.1 vs -5.8 NCT06309277
CGI-S, change (acute)
- BI 1569912
- —Not reported
- Blixeprodil
- —Not reported
MADRS response
- BI 1569912
- 34.8% vs 33.8%+1 vs placeboNCT06280235
5 other results
- 15.5% vs 11.3% NCT06280235
- 31.4% vs 33.8% NCT06280235
- 11.1% vs 11.3% NCT06280235
- 20.6% vs 33.8% NCT06280235
- 11.1% vs 11.3% NCT06280235
- Blixeprodil
- —Not reported
MADRS remission
- BI 1569912
- 21.2% vs 19.7%+1.5 vs placeboNCT06280235
2 other results
- 25.7% vs 19.7% NCT06280235
- 8.8% vs 19.7% NCT06280235
- Blixeprodil
- —Not reported
Relapse (% of patients)
- BI 1569912
- —Not reported
- Blixeprodil
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. BI 1569912: 4 of 4 rows · Blixeprodil: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | BI 1569912 | Blixeprodil |
|---|---|---|
| Dropout rate | 9.6%20 mga NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results7.3%10 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 12.5%5 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 9.6%20 mg NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 14.6%10 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 17.1%5 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5%20 mg NCT04937829 · Phase 1 15%5 mg NCT04937829 · Phase 1 | —210 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results—140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 —140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Discontinued due to AEs | 2.4%20 mga NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results4.9%10 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5%5 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 2.7%20 mg NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 4.9%10 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%5 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 —20 mg NCT04937829 · Phase 1 —5 mg NCT04937829 · Phase 1 | —210 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results—140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 —140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Serious AEs | 1.2%20 mga NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results2.4%10 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%5 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%20 mg NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 2.4%10 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%5 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%20 mg NCT04937829 · Phase 1 0%5 mg NCT04937829 · Phase 1 | 0%210 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results0%140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Most frequent reported AEs | 20 mga dizziness 8.4% (placebo 2.5%) headache 8.4% (placebo 6.3%) nasopharyngitis 4.8% (placebo 3.8%) NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results10 mg headache 4.9% (placebo 6.3%) upper respiratory tract infection 2.4% (placebo 6.3%) dizziness 0% (placebo 2.5%) NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5 mg headache 7.5% (placebo 6.3%) nasopharyngitis 7.5% (placebo 3.8%) upper respiratory tract infection 5% (placebo 6.3%) NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 20 mg headache 12.3% (placebo 7.9%) nasopharyngitis 8.2% (placebo 3.9%) diarrhoea 2.7% (placebo 1.3%) NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 10 mg headache 9.8% (placebo 7.9%) diarrhoea 4.9% (placebo 1.3%) nasopharyngitis 4.9% (placebo 3.9%) NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5 mg headache 14.3% (placebo 7.9%) diarrhoea 5.7% (placebo 1.3%) upper respiratory tract infection 5.7% (placebo 1.3%) NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 20 mg decreased appetite 5% (placebo 5.3%) blood pressure increased 0% (placebo 0%) constipation 0% (placebo 0%) NCT04937829 · Phase 1 5 mg blood pressure increased 10% (placebo 0%) constipation 10% (placebo 0%) headache 5% (placebo 5.3%) NCT04937829 · Phase 1 | 210 mg time perception altered 63.2% (placebo 0%) euphoric mood 57.9% (placebo 0%) hallucination, visual 57.9% (placebo 0%) NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results140 mg dizziness 46.5% (placebo 4.5%) euphoric mood 44.2% (placebo 0%) headache 37.2% (placebo 18.2%) NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 140 mg euphoric mood 61.1% (placebo 0%) dizziness 50% (placebo 4.5%) headache 50% (placebo 18.2%) NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
BI 1569912
show 5 more results
show 2 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BI 1569912's landscape · Blixeprodil's landscape